Your browser doesn't support javascript.
loading
Target fishing reveals PfPYK-1 and PfRab6 as potential targets of an antiplasmodial 4-anilino-2-trichloromethylquinazoline hit compound.
Kieffer, C; Primas, N; Hutter, S; Merckx, A; Reininger, L; Bach, S; Ruchaud, S; Gaillard, F; Laget, M; Amrane, D; Hervé, L; Castera-Ducros, C; Renault, J; Dumètre, A; Rault, S; Doerig, C; Rathelot, P; Vanelle, P; Azas, N; Verhaeghe, P.
Affiliation
  • Kieffer C; Normandie Univ, UNICAEN, CERMN, 14000 Caen, France.
  • Primas N; Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France; AP-HM, Service Central de la Qualité et de l'Information Pharmaceutiques, Hôpital Conception, Marseille 13005, France.
  • Hutter S; Aix Marseille Univ, IHU Méditerranée Infection, UMR VITROME, IRD, SSA, Mycology & Tropical Eucaryotic Pathogens, Marseille, France.
  • Merckx A; Université Paris Cité, MERIT, IRD, Paris, France.
  • Reininger L; Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France; Sorbonne Université, CNRS, FR2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Station Biologique de Roscoff, 29680 R
  • Bach S; Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France; Sorbonne Université, CNRS, FR2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Station Biologique de Roscoff, 29680 R
  • Ruchaud S; Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France; Sorbonne Université, CNRS, FR2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Station Biologique de Roscoff, 29680 R
  • Gaillard F; Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France; Sorbonne Université, CNRS, FR2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Station Biologique de Roscoff, 29680 R
  • Laget M; Aix Marseille Univ, INSERMN, SSA, MCT, Marseille, France.
  • Amrane D; Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France.
  • Hervé L; Université Paris Cité, MERIT, IRD, Paris, France.
  • Castera-Ducros C; Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France; AP-HM, Service Central de la Qualité et de l'Information Pharmaceutiques, Hôpital Conception, Marseille 13005, France.
  • Renault J; Université de Rennes - Faculté de Pharmacie, ISCR UMR CNRS 6226, Equipe CORINT, Rennes, France.
  • Dumètre A; Aix Marseille Univ, IHU Méditerranée Infection, UMR VITROME, IRD, SSA, Mycology & Tropical Eucaryotic Pathogens, Marseille, France.
  • Rault S; Normandie Univ, UNICAEN, CERMN, 14000 Caen, France.
  • Doerig C; School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
  • Rathelot P; Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France; AP-HM, Service Central de la Qualité et de l'Information Pharmaceutiques, Hôpital Conception, Marseille 13005, France.
  • Vanelle P; Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France; AP-HM, Service Central de la Qualité et de l'Information Pharmaceutiques, Hôpital Conception, Marseille 13005, France.
  • Azas N; Aix Marseille Univ, IHU Méditerranée Infection, UMR VITROME, IRD, SSA, Mycology & Tropical Eucaryotic Pathogens, Marseille, France. Electronic address: nadine.azas@univ-amu.fr.
  • Verhaeghe P; Univ. Grenoble Alpes, CNRS, DPM UMR 5063, F-38041 Grenoble, France; LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France; Service de Pharmacie, CHU de Nîmes, Place R. Debré, Nîmes, France. Electronic address: pierre.verhaeghe@univ-grenoble-alpes.fr.
Bioorg Med Chem ; 102: 117654, 2024 Mar 15.
Article in En | MEDLINE | ID: mdl-38452406
ABSTRACT
We present investigations about the mechanism of action of a previously reported 4-anilino-2-trichloromethylquinazoline antiplasmodial hit-compound (Hit A), which did not share a common mechanism of action with established commercial antimalarials and presented a stage-specific effect on the erythrocytic cycle of P. falciparum at 8 < t < 16 h. The target of Hit A was searched by immobilising the molecule on a solid support via a linker and performing affinity chromatography on a plasmodial lysate. Several anchoring positions of the linker (6,7 and 3') and PEG-type linkers were assessed, to obtain a linked-hit molecule displaying in vitro antiplasmodial activity similar to that of unmodified Hit A. This allowed us to identify the PfPYK-1 kinase and the PfRab6 GTP-ase as potential targets of Hit A.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Malaria, Falciparum / Antimalarials Limits: Humans Language: En Journal: Bioorg Med Chem Journal subject: BIOQUIMICA / QUIMICA Year: 2024 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Malaria, Falciparum / Antimalarials Limits: Humans Language: En Journal: Bioorg Med Chem Journal subject: BIOQUIMICA / QUIMICA Year: 2024 Document type: Article Affiliation country: France